{
    "clinical_study": {
        "@rank": "53713", 
        "arm_group": [
            {
                "arm_group_label": "Dose level A", 
                "arm_group_type": "Experimental", 
                "description": "Paclitaxel liposome injection 135mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days"
            }, 
            {
                "arm_group_label": "Dose level B", 
                "arm_group_type": "Experimental", 
                "description": "Paclitaxel liposome injection 175mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days"
            }, 
            {
                "arm_group_label": "Dose level C", 
                "arm_group_type": "Experimental", 
                "description": "Paclitaxel liposome injection 210mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days"
            }, 
            {
                "arm_group_label": "Dose level D", 
                "arm_group_type": "Experimental", 
                "description": "Paclitaxel liposome injection 250mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days"
            }, 
            {
                "arm_group_label": "Dose level E", 
                "arm_group_type": "Experimental", 
                "description": "Paclitaxel liposome injection 300mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days"
            }, 
            {
                "arm_group_label": "Comparator", 
                "arm_group_type": "Active Comparator", 
                "description": "Paclitaxel injection 175mg/m2 on day 1, each 21 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the maximum tolerated dose (MTD)of paclitaxel\n      liposome injection and to compare the pharmacokinetic characters between paclitaxel liposome\n      injection and paclitaxel injection and to value the effectiveness for cancer treatment."
        }, 
        "brief_title": "Dose Escalation and Pharmacokinetic Study of Paclitaxel Liposome Injection in Treating Patients With Advanced Solid Tumor After Failure From Conventional Treatments", 
        "condition": "Solid Tumors", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patient willing to sign an Investigational Review Board(IRB) approved written\n             informed consent document\n\n          -  patient age: 18 years -75years\n\n          -  patient must have histologically confirmed solid tumor\n\n          -  patient must have uncurable and unresectable solid tumor of advanced stages\n\n          -  patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n\n          -  patient must have a life expectancy at least 12 weeks\n\n          -  patient must have at least one lesion measurable according to Response Evaluation\n             Criteria in Solid Tumors (RECIST) 1.0\n\n          -  patient must have progress or recurrence after at least one chemotherapy regimen for\n             advanced stage\n\n          -  patient must have adequate marrow,hepatic and renal function: defined as ANC\u22652.0 \u00d7\n             109/L\uff0cPLT \u226510 \u00d7109/dL, Hb \u2265 9g/dL;GOT/GPT\u22642.5\u00d7ULN\uff1bToltle bilirubin \u22641.5\u00d7ULN; Serum\n             creatinine \u22641.5\u00d7ULN or Creatinine clearance\u226540ml/min(according to Cockcroft-Gault\uff1b\n\n          -  patient must have the left ventricular ejection fraction (LVEF)\u226550% confirmed by\n             ultrasonic heart scanning\n\n          -  women must have the negative pregnancy test; women and men must agree to use adequate\n             contraception\n\n        Exclusion Criteria:\n\n          -  patient must non have received any other antitumor therapy, including chemotherapy,\n             radiotherapy, hormonal therapy, biological therapy, immunotherapy and any other\n             investigational agent within 4 weeks prior to starting study\n\n          -  patient must non have any pre-existing toxity from prior antitumor therapy (any\u2265\n             grade 2, any\u22651 peripheral neuropathy, excluding alopecia)\n\n          -  patient must non have uncontrolled cerebral metastases\n\n          -  patient must non have any uncontrolled heart illness including, but not limited to,\n             ongoing symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, arterial hypertension (\u2265180/110), heart failure and myocardial infarction\n             within 6 months prior to starting study\n\n          -  Patient must not have a history of a malignancy tumor except for the following:\n             adequately treated localized basal cell or squamous cell carcinoma of the skin,\n             carcinoma in situ of the cervix for at least 5 years\n\n          -  patient must non have any serious illness including, but not limited to hepatic,\n             renal, respiratory and uncontrolled diabetes mellitus\n\n          -  patient must non have psychiatric illness/social situations that would limit\n             compliance with study requirements.\n\n          -  patient must non have active or uncontrolled infection including, but not limited to\n             tuberculosis,HIV,HBV, HCV\n\n          -  Patient must non be receiving any other antitumor agent\n\n          -  patient must non be pregnant and/or breastfeeding\n\n          -  patient must non be receiving protease inhibitors,inhibitors of CYP3A4,antifungal\n             agents and inducing agent of CYP3A4"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01994031", 
            "org_study_id": "NJLYSK-LPS-2013-01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Dose level A", 
                    "Dose level B", 
                    "Dose level C", 
                    "Dose level D", 
                    "Dose level E"
                ], 
                "intervention_name": "Paclitaxel liposome injection", 
                "intervention_type": "Drug", 
                "other_name": "LIPUSU\u00ae"
            }, 
            {
                "arm_group_label": "Comparator", 
                "intervention_name": "Paclitaxel injection", 
                "intervention_type": "Drug", 
                "other_name": "Taxol\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "paclitaxel liposome injection", 
            "paclitaxel"
        ], 
        "lastchanged_date": "April 28, 2014", 
        "location": {
            "contact": {
                "email": "goodjf@163.com", 
                "last_name": "Jifang Gong", 
                "phone": "008601088196561"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100142"
                }, 
                "name": "No.52 Fucheng Road, Haidian District,Beijing,"
            }, 
            "investigator": {
                "last_name": "Lin Shen", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "6", 
        "official_title": "Dose Escalation and Pharmacokinetic Study of Paclitaxel Liposome Injection in Treating Patients With Advanced Solid Tumor After Failure From Conventional Treatments", 
        "other_outcome": {
            "description": "Peak Plasma Concentration(Cmax), peak time (Tmax), Half life(T1/2), Area under the plasma concentration versus time curve(AUC0-t), Clearance (CL/F), Apparent volume of distribution(Vd/F), Mean Residence Time (MRT),", 
            "measure": "Pharmacokinetic characters of paclitaxel liposome injection compared with paclitaxel injection", 
            "safety_issue": "No", 
            "time_frame": "0,during infusion 1.5h, 3h, after infusion 15min, 30min, 1h,2h,4h,8h,12h,24h,36h,48h,72 h"
        }, 
        "overall_contact": {
            "email": "goodjf@163.com", 
            "last_name": "Jifang Gong", 
            "phone": "008601088196561"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Graded and described using National Cancer Institute(NCI)Common Terminology Criteria for adverse events (CTCAE 4.0)", 
            "measure": "Maximum tolerated dose(MTD)of paclitaxel liposome injection", 
            "safety_issue": "Yes", 
            "time_frame": "completion of cycle 1(28 days)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01994031"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Graded and described using National Cancer Institute(NCI)Common Terminology Criteria for adverse events (CTCAE 4.0)", 
            "measure": "dose-limiting toxicities(DLTs) of paclitaxel liposome injection", 
            "safety_issue": "Yes", 
            "time_frame": "completion of cycle 1 (28 days)"
        }, 
        "source": "Nanjing Luye Sike Pharmaceutical Co.,Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nanjing Luye Sike Pharmaceutical Co.,Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}